Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | Next generation of agents for lung cancer

Roy Herbst • 9 Sep 2020
Lung Cancer Non-Small Cell Lung Cancer Antibodies Pembrolizumab Ramucirumab Sotorasib

Roy Herbst, MD, PhD, FACP, FASCO, of Yale University, New Haven, CT, discusses the next generation of agents for lung cancer as presented in the 20th annual Internation Lung Cancer Congress (ILCC) 2020. Prof. Herbst updates us on the use of the KRAS(G12C) inhibitor, AMG 510, in lung cancer, combination immunotherapy and the importance of identifying novel checkpoint targets including siglec-15. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Roy Herbst

5:27
Immunotherapy trial updates in NSCLC from ESMO 2020
Roy Herbst • 9 Sep 2020
2:33
ADAURA: osimertinib adjuvant therapy in EGFR mutated NSCLC
Roy Herbst • 9 Sep 2020
2:48
JVDF: immune profiling and clinical outcomes in patients treated with ramucirumab and pembrolizumab
Roy Herbst • 26 May 2020
8:06
ADAURA: osimertinib post-tumor resection in NSCLC
Roy Herbst • 26 May 2020

Related Videos

1:03
The benefits of liquid biopsies for lung cancer in the community setting
Deepti Behl • 9 Apr 2024
0:57
STK-012-101: STK-012 in advanced solid tumors
Alexander Spira • 15 Mar 2024
3:34
FLAURA2: EGFRm dynamics in NSCLC treated with osimertinib
Pasi Jänne • 8 Apr 2024
0:54
FURVENT: furmonertinib in EGFR exon 20 mutant NSCLC
Alexander Spira • 15 Mar 2024
The content of VJOncology is intended for healthcare professionals